8-K Announcements
6Material company update
Jun 26, 2026·SEC
Material company update
May 22, 2026·SEC
Material company update
May 15, 2026·SEC
Anavex Life Sciences Corp.(AVXL)Earnings, Financials & Key Ratios
AVXL•NASDAQ
$2.71
Price updated Jul 7, 2026
AboutAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$46M-7.8%
- Net Income-$46M-7.8%
- EPS (Diluted)-0.54-3.8%
- ROE-43.11%-31.4%
AVXL Price & Volume
Anavex Life Sciences Corp. (AVXL) stock price & volume — 10-year historical chart
Loading chart...
Persistent R&D Burn Challenges Clinical Development Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary Clinical Trial Outcomes
Key Thesis Takeaways
- Anavex Life Sciences remains a pre-revenue biotechnology firm entirely dependent on external financing to fund its late-stage CNS pipeline, as evidenced by cumulative retained earnings losses of $388.1 million.
- While the company maintains a debt-free balance sheet, the consistent quarterly R&D expenditure—peaking at $11.8 million—creates significant binary risk regarding future regulatory approvals.
- Investors should monitor the company's ability to manage its $131.7 million cash position against ongoing operational losses before further dilutive equity issuance becomes necessary.
Verdict Logic
the company's reliance on equity-linked financing to cover quarterly R&D costs of up to $11.8 million presents substantial dilution risk to shareholders in the absence of commercial revenue.
AVXL Growth Metrics
Anavex Life Sciences Corp. (AVXL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.67%
Return on Capital
10 Years-41.86%
5 Years-41.86%
3 Years-42.45%
Last Year-47.79%
AVXL Recent Earnings
Anavex Life Sciences Corp. (AVXL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q3 2026Latest
Jun 30, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
Q3 2026
Jun 23, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
Q3 2026
Jun 16, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
Q3 2026
Jun 9, 2026Metric
Actual
Est
EPS
$0.07+0.0%
$0.07
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 30, 2026 | $0.07vs $0.07+0.0% | — |
| Q3 2026 | Jun 23, 2026 | $0.07vs $0.07+0.0% | — |
| Q3 2026 | Jun 16, 2026 | $0.07vs $0.07+0.0% | — |
| Q3 2026 | Jun 9, 2026 | $0.07vs $0.07+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Anavex Life Sciences Corp. (AVXL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.71 | $251.14M | -5.02 | — | — | -43.11% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $1.03 | $32.32M | -0.95 | — | -26078.89% | -218.67% | — | |
| $205.70 | $30.37B | 23.30 | 1.39% | 13.92% | 7.55% | — |
Compare AVXL vs Peers
Anavex Life Sciences Corp. (AVXL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVXL SEC Filings & Documents
Anavex Life Sciences Corp. (AVXL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AVXL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVXL Frequently Asked Questions
Anavex Life Sciences Corp. (AVXL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AVXL profitable?
Anavex Life Sciences Corp. (AVXL) reported a net loss of $39.9M for fiscal year 2025.
Dividend & Returns
What is AVXL's return on equity?
Anavex Life Sciences Corp. (AVXL) has a return on equity (ROE) of -43.1%. Negative ROE indicates the company is unprofitable.
What is Anavex Life Sciences Corp.'s free cash flow?
Anavex Life Sciences Corp. (AVXL) had negative free cash flow of $34.1M in fiscal year 2025, likely due to heavy capital investments.